Table 3. Cox proportional stepwise multivariate analysis for the association between the variables and time to CRPC.
| Unadjusted | Adjusted | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Comparison | Time to CRPC in months (median) | HR (95% CI) | p-value | HR (95% CI) | p-value | ||||
| Presence of metastasis at initial diagnosis | vs | No metastasis | 26.6 | vs | not reached | 7.00 (4.47–10.97) | <0.001 | 4.79 (2.93–7.83) | <0.001 |
| PSA ≥20 ng/mL | vs | PSA <20 ng/mL | 53.5 | vs | not reached | 4.93 (2.75–8.84) | <0.001 | 2.48 (1.29–4.73) | 0.006 |
| Gleason score ≥8 | vs | Gleason score ≤7 | 56.8 | vs | not reached | 3.88 (2.19–6.85) | <0.001 | 2.17 (1.20–3.91) | 0.010 |
Abbreviations: CRPC, castration resistant prostate cancer; HR, hazard ratio; CI, confidence interval; NA, not applicable; PSA, prostate-specific antigen.